Benitec Biopharma dismisses Baker Tilly, appoints Ernst & Young as auditor

Benitec Biopharma Inc.

Dismissed Baker Tilly on Sept 18, 2026; appointed EY for fiscal year ending June 30, 2027.
Baker Tilly's FY2025/FY2026 audit reports were unqualified, with no disagreements.
Prior material weakness in share-based compensation controls was remediated as of June 30, 2026.
No consultations with EY on accounting matters; engagement subject to EY client acceptance.
Company cites good corporate governance as reason for auditor transition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.